"description","instanceType","name","id","label","uuid:ID","rationale"
"The main design for the study","StudyDesign","Study Design 1","StudyDesign_1","","bacde034-574c-43c4-bc5d-219f59b36c65","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated."
